MwanzoNVV1 • FRA
add
Novavax Inc
Bei iliyotangulia
€ 11.02
Bei za siku
€ 10.86 - € 10.86
Bei za mwaka
€ 3.38 - € 23.93
Thamani ya kampuni katika soko
1.67B USD
Wastani wa hisa zilizouzwa
elfu 13.13
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Kwenye habari
InvestorPlace
wiki 1 iliyopita
Novavax’s Second Act: How a Fallen COVID Star Could Rise from the Ashes
0.42%
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Mac 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 93.86M | 15.94% |
Matumizi ya uendeshaji wa biashara | 82.30M | -26.87% |
Mapato halisi | -147.55M | 49.80% |
Kiwango cha faida halisi | -157.21 | 56.70% |
Mapato kwa kila hisa | -1.05 | 69.21% |
EBITDA | -126.58M | 58.32% |
Asilimia ya kodi ya mapato | -1.56% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Mac 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 480.59M | -23.10% |
Jumla ya mali | 1.35B | -12.26% |
Jumla ya dhima | 2.22B | -8.93% |
Jumla ya hisa | -867.08M | — |
hisa zilizosalia | 140.40M | — |
Uwiano wa bei na thamani | -1.78 | — |
Faida inayotokana na mali | -22.01% | — |
Faida inayotokana mtaji | 96.03% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Mac 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -147.55M | 49.80% |
Pesa kutokana na shughuli | -83.56M | 74.34% |
Pesa kutokana na uwekezaji | -7.25M | 69.22% |
Pesa kutokana na ufadhili | 5.89M | 101.66% |
Mabadiliko halisi ya pesa taslimu | -87.87M | 87.66% |
Mtiririko huru wa pesa | -552.90M | -64.08% |
Kuhusu
Novavax, Inc. is an American biotechnology company based in Gaithersburg, Maryland, that develops vaccines to counter serious infectious diseases. Prior to 2020, company scientists developed experimental vaccines for influenza and respiratory syncytial virus, as well as Ebola and other emerging infectious diseases. During 2020, the company redirected its efforts to focus on development and approval of its NVX-CoV2373 vaccine for COVID-19.
The COVID-19 vaccine Nuvaxovid was approved in the European Union at the end of 2021, and in Canada in February 2022, as the fifth vaccine against COVID-19, following Pfizer/BioNTech, Moderna, Janssen and AstraZeneca. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
1987
Makao Makuu
Tovuti
Wafanyakazi
1,543
